Table 5.
Formulation | Evaluation parameters | Observations (months) | |||
---|---|---|---|---|---|
0 | 1 | 2 | 3 | ||
L-SMEF (F9) | Physical appearance | Pale yellow clear liquid | Pale yellow clear liquid | Pale yellow clear liquid | Pale yellow clear liquid |
Globule size (nm) | 127 ± 16 | 130 ± 24 | 132 ± 13 | 133 ± 32 | |
Total drug content | 100.0 ± 1.4 | 99.51 ± 0.9 | 99.50 ± 1.0 | 99.48 ± 1.2 | |
| |||||
S-SMSD | Physical appearance | White powder | White powder | White powder | White powder |
Globule size | 133 ± 28 | 135 ± 42 | 136 ± 24 | 136 ± 14 | |
Total drug content | 100.0 ± 0.9 | 99.29 ± 1.2 | 99.09 ± 1.1 | 99.02 ± 0.9 | |
| |||||
S-SMFD | Physical appearance | White powder | White powder | White powder | White powder |
Globule size | 160 ± 37 | 162 ± 23 | 163 ± 21 | 165 ± 34 | |
Total drug content | 100.0 ± 0.9 | 99.10 ± 0.8 | 99.08 ± 1.3 | 99.03 ± 1.6 |